{"hq_id":"hq-p-spe-000198","name":"CBD Oil (Cannabidiol Oil, Contamination and Mislabeling, THC Content Variability, Drug Interactions, Unregulated Market)","category":{"primary":"cannabis","secondary":"cbd_oil","tags":["CBD","cannabidiol","hemp","oil","tincture","contamination","mislabeling","THC","drug interaction","CYP450","liver","unregulated"]},"product_tier":"SPE","overall_risk_level":"moderate","description":"CBD (cannabidiol) oil has become a multi-billion-dollar consumer product marketed for anxiety, pain, sleep, and inflammation, available as tinctures, capsules, gummies, topicals, and pet products from thousands of manufacturers operating in a largely unregulated market. Despite the 2018 Farm Bill legalizing hemp-derived CBD, the FDA has not approved CBD as a food additive or dietary supplement (Epidiolex remains the only FDA-approved CBD product, for epilepsy). This regulatory vacuum has created systematic quality control failures: a landmark 2017 JAMA study found that 69% of CBD products tested were mislabeled — 43% contained less CBD than claimed and 26% contained more, while 21% contained detectable THC not disclosed on the label. Contamination with pesticides, heavy metals, residual solvents, and synthetic cannabinoids has been documented in multiple independent surveys. CBD is not pharmacologically inert — it is a potent inhibitor of cytochrome P450 enzymes (CYP3A4, CYP2C19, CYP2C9, CYP1A2), causing clinically significant interactions with warfarin, clobazam, valproate, immunosuppressants, and many other medications. FDA-approved Epidiolex carries a black box warning for hepatotoxicity at doses above 10 mg/kg/day, and liver enzyme elevation has been documented in clinical trials.","synthesis":{"derived_risk_level":"high","synthesis_confidence":0.5,"synthesis_method":"compound_composition","context_used":"human_child","context_source":"product_users","exposure_modifier":1.15,"vulnerability_escalated":true,"escalation_reason":"Child exposure group","compounds_resolved":1,"compounds_total":1,"synthesis_date":"2026-05-09","synthesis_version":"1.2.0","methodology_note":"exposure_modifier and adjusted_magnitude are computed from ALETHEIA-calibrated heuristics (route × duration × frequency multipliers, clamped to [0.5, 1.4]). Multipliers are directionally informed by EPA Exposure Factors Handbook (2011) and CalEPA OEHHA but are not regulatory consensus. See /api/methodology for full disclosure."},"hazard_summary":{"sensitive_populations":"patients on warfarin, clobazam, valproate, immunosuppressants, or other CYP3A4/CYP2C19/CYP2C9-metabolized drugs; individuals subject to drug testing; children; liver disease patients; pets (CBD toxicity data limited)","overall_risk":"moderate","primary_concerns":["69% of CBD products mislabeled — 43% under-labeled for CBD, 21% contain undisclosed THC","Potent CYP450 inhibition causes clinically significant drug interactions with warfarin, clobazam, and others","FDA-approved Epidiolex carries hepatotoxicity black box warning at therapeutic doses","Unregulated market allows contamination with pesticides, heavy metals, solvents, and synthetic cannabinoids"],"exposure_routes":"Ingestion (primary — tinctures, capsules, gummies with systemic CBD absorption and CYP450 inhibition). Dermal (topicals with variable systemic absorption)."},"exposure":{"routes":["ingestion","dermal"],"contact_types":["ingestion_direct","dermal_direct"],"users":["adult","elderly","medical_patient","child","pet"],"duration":"chronic","frequency":"daily","scenarios":["Patient taking warfarin begins daily CBD oil — CYP3A4/CYP2C19 inhibition increases warfarin levels, causing dangerous INR elevation and bleeding risk","Consumer purchases CBD oil containing undisclosed THC — fails workplace drug test","User takes CBD product contaminated with heavy metals and pesticide residues from unregulated hemp cultivation","Parent gives child CBD gummies for sleep — product contains less CBD than labeled and significant THC"],"notes":"Market scale: US CBD market estimated at $5.3 billion (2022). Regulatory status: FDA has not approved CBD as dietary supplement or food additive; enforcement discretion for low-risk products. Bonn-Miller et al. (JAMA 2017): 69% mislabeled (84 products tested; 43% under-labeled, 26% over-labeled for CBD; 21% contained THC). CYP450 inhibition: CBD IC50 for CYP3A4 = 1-3 uM (clinically achievable). Warfarin interaction: case reports of INR doubling within 2 weeks of CBD initiation. Epidiolex label: hepatotoxicity warning, liver enzyme monitoring required. Contamination: CBD products have tested positive for dextromethorphan, 5F-ADB (synthetic cannabinoid), and undisclosed THC."},"consumer_guidance":{"usage_warning":"If you take ANY prescription medications, consult your physician or pharmacist before using CBD products — CBD inhibits the same liver enzymes that metabolize warfarin, anti-seizure drugs, immunosuppressants, and many other medications. Demand third-party certificate of analysis (COA) showing CBD content, THC content, pesticides, heavy metals, and residual solvents. Purchase only from companies that publish batch-specific COA from ISO-certified labs. If subject to drug testing, be aware that 21% of CBD products contain undisclosed THC. Do not give CBD products to children without physician supervision.","safer_alternatives":["FDA-approved Epidiolex (pharmaceutical-grade CBD for epilepsy — prescription only)","USP-verified supplements for anxiety/sleep (melatonin, valerian, magnesium)","Third-party certified CBD isolate products from transparent manufacturers","Consult physician for evidence-based treatments for target conditions"]},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA","regulation":"FDA Position on CBD in Food, Supplements, and Consumer Products","citation":"FD&C Act Sections 201(ff), 301(ll); FDA Consumer Updates on CBD (2019-2023); 2018 Farm Bill Section 10113","requirements":"FDA maintains that CBD cannot be lawfully marketed as a dietary supplement or added to food because it was first studied as a drug (Epidiolex). FDA has exercised enforcement discretion for most CBD products but has issued warning letters to companies making disease claims. The 2018 Farm Bill legalized hemp cultivation and hemp-derived products but did not override FDA authority over food and drug regulation. FTC has taken action against CBD companies for deceptive advertising. No federal manufacturing, potency, or purity standards exist for consumer CBD products.","compliance_status":null,"effective_date":null,"enforcing_agency":"FDA, FTC","penalties":null,"source_ref":null}],"certifications":[],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":true,"disposal_guidance":"Dispose of expired or unwanted CBD products in regular trash. Glass tincture bottles are recyclable.","hazardous_waste":false,"expected_lifespan":"CBD oil: 12-24 months unopened; 6 months after opening if stored cool and dark. Gummies: 6-12 months."},"formulation":{"form":"varies","key_ingredients":[],"certifications":[]},"materials":{"common":[],"concerning":[],"preferred":[]},"compound_composition":[{"hq_id":"hq-c-org-000081","compound_name":null,"role":"contaminant","typical_concentration":"21% of CBD products contain undisclosed THC (JAMA 2017); poses workplace drug test failure and unintended psychoactive exposure risks"}],"identifiers":{"common_names":["cbd oil (cannabidiol oil, contamination and mislabeling, thc content variability, drug interactions, unregulated market)"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[],"brand_examples_disclaimer":null,"sources":[{"type":"expert_curation","name":"ALETHEIA Safety Database","date":"2026-03-26"}],"meta":{"schema_version":"4.0.0","last_updated":"2026-03-26","timestamp":"2026-05-14T01:22:38.522Z"}}